Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Chmp save search
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
Published: 2024-03-22 (Crawled : 15:30) - globenewswire.com
ESPR | $2.08 8.9% 8.17% 4.9M
|
Health Technology
|
| O: 0.0%
H: 13.74%
C: 8.53%
chmp positive hypercholesterolemia cardiovascular
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: 2.26%
H: 0.0%
C: -2.65%
chmp positive cancer treatment
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 52.98%
H: 8.82%
C: -19.87%
ons-5010 therapeutics chmp positive treatment
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
fabhalta first chmp positive novartis
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-02-26 (Crawled : 11:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
lung chmp positive cancer cell treatment
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
LEGN | News | $47.42 0.77% 0.76% 1.8M
|
Health Technology
|
| O: 2.07%
H: 5.02%
C: 4.92%
carvykti chmp biotech positive treatment therapy
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.25%
H: 2.95%
C: 2.88%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.43%
H: 1.06%
C: -0.05%
qalsody first chmp genetic positive treat therapy
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
TVTX | $5.745 -1.8% -1.83% 1.2M
|
Health Technology
|
| O: 3.69%
H: 1.07%
C: -2.58%
nephropathy chmp positive treatment therapeutics
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
Published: 2024-02-23 (Crawled : 07:00) - prnewswire.com
TVTX | $5.745 -1.8% -1.83% 1.2M
|
Health Technology
|
| O: 3.69%
H: 1.07%
C: -2.58%
nephropathy chmp positive treatment therapeutics
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.71%
H: 0.48%
C: -0.52%
chmp positive cell therapy
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
Published: 2024-01-26 (Crawled : 12:00) - globenewswire.com
APLS G | $48.69 2.2% 2.16% 1.2M
|
Health Technology
|
| O: -0.35%
H: 0.41%
C: -3.0%
chmp application negative
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
Published: 2024-01-25 (Crawled : 21:00) - prnewswire.com
PTCT | News S | $25.38 -2.27% -2.32% 750K
|
Health Technology
|
| O: -3.56%
H: 5.83%
C: 5.21%
chmp authorization negative
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Published: 2023-12-15 (Crawled : 22:00) - biospace.com/
VRTX | $404.93 1.25% 1.43% 1.1M
|
Health Technology
|
| O: 0.38%
H: 0.84%
C: 0.62%
first disease chmp positive cell treatment
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2023-12-15 (Crawled : 21:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.64%
H: 0.21%
C: -1.79%
hyqvia chmp positive therapy
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
Published: 2023-12-15 (Crawled : 14:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.31%
H: 0.98%
C: -3.58%
skyclarys rare first disease chmp positive treat neurodegenerative therapy
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
MDWD | $16.345 3.71% 3.58% 21K
|
Health Technology
|
| O: -0.15%
H: 4.18%
C: 2.36%
nexobrid chmp approval positive treat
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
Published: 2023-11-10 (Crawled : 14:30) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 0.12%
H: 7.18%
C: 3.56%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -0.22%
H: 0.86%
C: 0.86%
biosimilar chmp positive stelara
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published: 2023-11-10 (Crawled : 14:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: 0.45%
H: 0.51%
C: -1.41%
keytruda chmp merck positive cancer treatment plus gemcitabine
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
Published: 2023-11-10 (Crawled : 13:00) - prnewswire.com
BPMC | $92.32 1.89% 1.85% 790K
|
Health Technology
|
| O: 1.15%
H: 2.66%
C: 1.62%
ayvakyt chmp positive therapy
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.